Navigation Links
Catalyst Pharmaceutical Partners, Inc. Announces a $4.5 Million Registered Direct Common Stock Offering
Date:9/12/2008

r of high quality institutional investors. The offering will allow us to accelerate the non-clinical development program we believe will be required for us to file an NDA for CPP-109, broaden our pilot study program and provide us with additional financial strength as we move forward with our business activities including ongoing discussions with potential strategic partners."

The securities described above are being offered by Catalyst pursuant to a previously filed shelf registration statement on Form S-3 that was declared effective by the Securities and Exchange Commission on June 26, 2008. The shares of common stock may only be offered by means of a prospectus supplement and accompanying prospectus, forming a part of the effective shelf registration statement. Copies of the base prospectus and the prospectus supplement for the offering can be obtained from Rodman & Renshaw, LLC, 1251 Avenue of the Americas, New York, New York, 10020, or by calling (212) 356-0549. An electronic copy of the prospectus and prospectus supplement will also be available on the website of the Securities and Exchange Commission at http://www.sec.gov.

This press release does not and shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

About Catalyst Pharmaceutical Partners

Catalyst Pharmaceutical Partners, Inc. is a biopharmaceutical company focused on the development and commercialization of prescription drugs for the treatment of addiction and obsessive compulsive disorders. The Company has obtained from Brookhaven National Laboratory an exclusive worldwide license for Brookhaven's patent portfolio in the United States relating to the right to use vigabatrin to treat a w
'/>"/>

SOURCE Catalyst Pharmaceutical Partners, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NIST and partners identify tiny gold clusters as top-notch catalysts
2. Catalyst Pharmaceutical Partners Reports Second Quarter 2008 Financial Results
3. Controlling the size of nanoclusters: First step in making new catalysts
4. Catalyst Pharmaceutical Partners, Inc. Files Form S-3 Shelf Registration Statement
5. IDEXX Laboratories Announces First Customer Deliveries of Catalyst Dx(TM) Chemistry Analyzer and SNAPshot Dx(TM) Analyzer
6. UCT Specialties (Formerly Petrarch) Announces the Release of Their New Product Guides for Silanes, Silicones, Platinum Catalyst and Glass Coatings
7. Experiments reveal unexpected activity of fuel cell catalysts
8. Using catalysts to stamp nanopatterns without ink
9. Simcere Pharmaceutical Group Announces Two Senior Promotions and Appointment of New Vice President of Human Resources
10. Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
11. BioMarin to Present at the Merrill Lynch Global Pharmaceutical Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... May 05, 2015 VetStem Biopharma, ... Animal Health, Jeffrey Schaffer, DVM, as Director of ... 15 years of experience in the veterinary regenerative ... addition to our veterinarian lead organization”. Dr. ... “Dr. Schaffer will be responsible for all technical ...
(Date:5/5/2015)... May 05, 2015 Research and Markets ... the addition of the "Separation Systems ... offering. Macromolecules which include protein, ... or are broken into smaller molecules, during ... separation requires various advanced systems like centrifugation, ...
(Date:5/5/2015)... 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) today ... trading on OTCQB  Marketplace, the market for developmental ... for a continuous public market for trading shares ... quotes and market information on us through ... includes U.S. and international companies in venture stage, ...
(Date:5/5/2015)... SAN DIEGO , May 5, 2015 /PRNewswire-USNewswire/ ... treatments for congestive heart failure and other chronic ... create an independent analysis designed to reflect the ... over time. This model will be used to ... for CHF, could have on those groups of ...
Breaking Biology Technology:Leading Regenerative Veterinary Medicine Company, VetStem Biopharma announces the addition of Dr Jeffrey Schaffer as the Director of Veterinary Professional Services. 2Global Separation Systems Market in Biotechnology 2015-2019 - Trends and Forecasts for the $28 Billion Market 2Tikcro Technologies Announces Approval to Continue Trading on OTCQB 2RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate 2RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate 3
... a company developing next generation biologics for the treatment and ... OPTiM (OncoVEX Pivotal Trial in Melanoma) Phase 3 study with ... Stage IV melanoma had initiated. The study has commenced recruiting ... Germany and Australia due to open later in the year. ...
... Zenobia Therapeutics, Inc., the leader in fragment-based lead ... announced successful completion of the first phase of ... subsidiary of Biogen Idec (Nasdaq: BIIB ... access to Zenobia,s technology and expertise in structural ...
... OAKWOOD VILLAGE, Ohio, April 14 ViewRay Incorporated, a ... tranche of their $25M Series B financing. Funding was ... towards the development of their image guided cancer therapy ... OrbiMed Advisors and Fidelity Biosciences, and was joined by ...
Cached Biology Technology:BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma 2BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma 3BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma 4Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals 2ViewRay Incorporated Closes $15M Tranche of Series B Financing and Announces Partnership with Siemens AG 2
(Date:4/20/2015)... Huntington Memorial Hospital is the first facility ... miniaturized, wireless monitoring sensor to manage heart failure (HF). ... FDA-approved heart failure monitoring device that has been proven ... to manage heart failure. The CardioMEMS HF ... pulmonary artery (PA) during a non-surgical procedure to directly ...
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. today ... (FIDO ® ) Alliance tm , an industry ... members commit to share technology and collaborate to ... are interoperable, more secure and private, and easier ... identity verification that protects sensitive user information and ...
(Date:4/13/2015)... , April 13, 2015  higi, a leading cloud-based ... to more fully engage with their communities around health ... privacy protected and secure API.  ... the most accessible, affordable, and convenient vehicle to receive ... The API will allow higi,s ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3
... up to an undergraduate class, being given a dissertation ... improve on it. This was the experience ... London,s) Department of Science and Technology Studies between 2000 ... teaching is a full-blown academic monograph published this month ...
... microscopy to a major marine biology challenge, researchers ... and attack patterns of two tiny but deadly ... Bay and other waterways. The study, reported ... Proceedings of the National Academy of Sciences, focused ...
... standards for phosphorus releases into the Everglades seem sufficient ... from damage, but pollutant levels still reach double or ... edges. A six-year study led by Duke University ... in two research sites inside the Everglades. In ...
Cached Biology News:Researchers view swimming tactics of tiny aquatic predators 2Researchers view swimming tactics of tiny aquatic predators 3Everglades phosphorus limits on the right track, but more is needed 2Everglades phosphorus limits on the right track, but more is needed 3
... Reduce bench time to just 15 minutes! ... paralles that can be drawn between this exciting ... of instant foods. Instant meals consumed by ... format and are reconstituted by adding water. ...
...
Request Info...
Automated -80° C sample library for microplates and cryotube racks in SBS format; for integration into automated processes....
Biology Products: